Indications and Usage

Angiomax® (bivalirudin) is indicated for the following uses¹:

• ANGIOMAX is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA)
• ANGIOMAX with provisional use of glycoprotein llb/llla is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI)
• ANGIOMAX is indicated for patients with or at risk for, heparin-induced thrombocytopenia and thrombosis syndrome undergoing PCI
• ANGIOMAX is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin

The safety and effectiveness of ANGIOMAX have not been established in patients with acute coronary syndromes who are not undergoing PTCA or PCI.

ANGIOMAX should not be used in patients with the following:

• Active major bleeding
• Hypersensitivity to ANGIOMAX or its components

Visit the Dosage and Administration section for more information about ANGIOMAX.

Safety Considerations

ANGIOMAX with provisional use of glycoprotein IIb/IIIa inhibitor is indicated for use as an anticoagulant in patients undergoing percutaneous coronary intervention (PCI), and in patients with or at risk for heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing PCI. ANGIOMAX is intended for use with aspirin and has been studied only in patients receiving concomitant aspirin. ANGIOMAX is contraindicated in patients with active major bleeding or hypersensitivity to ANGIOMAX or its components. The most common (10%) adverse events for ANGIOMAX were back pain, pain, nausea, headache, and hypotension. An unexplained fall in blood pressure or hematocrit, or any unexplained symptom, should lead to serious consideration of a hemorrhagic event and cessation of ANGIOMAX administration. Please see complete prescribing information.